MANGOCEUTICALS, INC.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | (Audited) | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $101,019 | $58,653 |
| Deposits | 16,942 | 16,942 |
| TOTAL CURRENT ASSETS | 117,961 | 75,595 |
| NON-CURRENT ASSETS | ||
| Property and equipment, net of accumulated depreciation of $2,758 and $2,256 | 2,304 | 2,806 |
| Right of use - asset | 27,670 | 59,493 |
| Intangible assets - acquired patents and license, net of amortization | 20,694,893 | 15,232,617 |
| TOTAL NON-CURRENT ASSETS | 20,724,867 | 15,294,916 |
| TOTAL ASSETS | $20,842,828 | $15,370,511 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | 767,996 | 837,501 |
| Accrued liabilities - related parties | 30,000 | - |
| Payroll tax liabilities | 2,973 | - |
| Notes payable | 500,000 | 150,000 |
| Notes payable - related parties | 100,000 | - |
| Right-of-use liability - operating lease | 30,117 | 64,962 |
| Other liabilities - patent purchase payable | 160,684 | 373,000 |
| Other liabilities - related parties | 9,175 | - |
| TOTAL CURRENT LIABILITIES | 1,600,945 | 1,425,463 |
| TOTAL LIABILITIES | 1,600,945 | 1,425,463 |
| COMMITMENTS AND CONTINGENCIES (SEE NOTE 9) | - | - |
| STOCKHOLDERS’ EQUITY | ||
| Series B Convertible Preferred stock, (par value $0.0001), 6,000 shares authorized, 582 and 2,770 shares were issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | - | - |
| Series C Convertible Preferred stock, (par value $0.0001), 6,250,000 shares authorized, 980,000 and 980,000 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 98 | 98 |
| Common stock (par value $0.0001), 200,000,000 shares authorized, of which 10,644,457 and 3,245,641 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 1,065 | 325 |
| Stock warrants | 324,288 | 324,288 |
| Subscriptions receivable | (224,569) | (1,150,000) |
| Additional paid-in capital | 50,794,020 | 35,587,858 |
| Accumulated deficit | (31,649,804) | (20,806,595) |
| Accumulated other comprehensive loss | (2,034) | (9,845) |
| TOTAL STOCKHOLDERS’ EQUITY | 19,243,064 | 13,946,129 |
| Non-controlling interest | (1,181) | (1,081) |
| TOTAL STOCKHOLDERS’ EQUITY ATTRIBUTABLE TO MANGOCEUTICALS, INC. STOCKHOLDERS | 19,241,883 | 13,945,048 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $20,842,828 | $15,370,511 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.